Supernus Announces Second Quarter 2024 Financial Results
06 août 2024 16h06 HE
|
Supernus Pharmaceuticals, Inc.
Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second quarter and first six months of...
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
01 août 2024 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
23 juil. 2024 16h13 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
30 mai 2024 16h25 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
23 mai 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May ...
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
09 mai 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2024 Financial Results
08 mai 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6 million. Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales...
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
01 mai 2024 08h00 HE
|
Supernus Pharmaceuticals, Inc.
Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled...
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
24 avr. 2024 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Provides Regulatory Update for SPN-830
08 avr. 2024 08h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...